Christine Janson

Christine Janson is a highly experienced professional in the field of bioconjugate pharmacology and oncology, currently serving as the Director of Bioconjugate Pharmacology at Exelixis since May 2023. Prior to this, Christine held the position of Director of Non-clinical Oncology at Kriya Therapeutics, Inc., and was retained as a part-time consultant after the oncology team's layoff. With a robust background in translational medicine, Christine served as Associate Director at 4D Molecular Therapeutics and progressed through several roles at Gritstone Oncology, focusing on bispecific antibodies for cancer treatment. Experience includes previous roles at ChemoCentryx as a Scientist investigating immuno-oncology and a postdoctoral scholar at the University of California, San Francisco, where novel cancer drugs were tested. Christine's academic qualifications include a PhD in Molecular Biology from UCLA and a BS in Biology from Truman State University.